Suppliers and packagers for vtama

vtama

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272	NDA	Organon LLC	81672-5051-1	1 TUBE in 1 PACKAGE (81672-5051-1) / 60 g in 1 TUBE	2025-05-28

Last updated: July 30, 2025

ppliers for the Pharmaceutical Drug: VTAMA

Introduction

VTAMA, the brand name for Tapinarof cream, is a topical medication developed by Dermavant Sciences for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. As a relatively new entrant in the dermatology space, understanding its suppliers—ranging from raw material providers to manufacturing partners—is essential for stakeholders involved in the supply chain, procurement, and investment decisions. This analysis details the key suppliers associated with VTAMA, their roles, and strategic implications for the pharmaceutical ecosystem.

Manufacturing and Formulation Suppliers

The production of VTAMA involves multiple stages, including active pharmaceutical ingredient (API) synthesis, formulation into topical cream, packaging, and distribution. As of the latest available data, Dermavant Sciences has collaborated with specialized contract manufacturing organizations (CMOs) and suppliers to ensure supply chain robustness.

• API Supplier: Tapinarof
  Tapinarof is a novel aryl hydrocarbon receptor (AhR) agonist, and its synthesis requires specialized chemical manufacturing capabilities. Although Dermavant has not publicly disclosed its primary API supplier, industry sources speculate that the API procurement is localized within North America or Europe, where chemical synthesis of complex pharmaceuticals is standardized.

• Formulation and Fill-Finish Suppliers
  For the topical cream formulation and packaging, Dermavant partners with CDMOs experienced in dermatological products. These suppliers provide formulation expertise, sterile manufacturing, and fill-finish services. Notably:

  • Kymos is one prominent US-based CMO with capabilities in topical drug manufacturing.
  • Recipharm and Catalent are also potential partners, given their extensive dermatology manufacturing portfolios, although specific collaborations for VTAMA have not been officially confirmed.

Raw Material Suppliers

The manufacturing of VTAMA cream involves several raw materials, including excipients such as emollients, stabilizers, preservatives, and emulsifiers. These quality-critical components require high purity and compliance with pharmacopeial standards.

• Emollients and Oils
  Suppliers like BASF and Evonik serve as sources for emollient base components, which influence the cream’s viscosity and skin absorption.

• Preservatives
  Compounds like parabens or phenoxyethanol are sourced from multiple chemical suppliers globally, ensuring regulatory compliance.

• Active Ingredient (API) Synthesis
  The raw chemical precursors for Tapinarof are sourced from specialized chemical suppliers with expertise in synthesizing heterocyclic compounds, though specific supplier identities remain undisclosed due to confidentiality agreements.

Distribution and Supply Chain Partners

Post-production, VTAMA’s distribution relies heavily on logistics firms with expertise in pharmaceuticals.

• Distribution Channels
  Major pharmaceutical distributors such as McKesson, Cardinal Health, and AmerisourceBergen facilitate the distribution across North America, ensuring compliance with cold chain and storage requirements.

• Regulatory and Quality Assurance
  Suppliers also include third-party auditors and certifiers that verify GMP compliance, such as UL International and GMP Compliance Inc.

Strategic Supplier Relationships and Risks

Given the relatively recent market entry of VTAMA (approved by the FDA in April 2022), Dermavant has emphasized establishing diversified supply chains to mitigate risks associated with raw material shortages, geopolitical disruptions, and regulatory hurdles.

• Diversification Strategy
  The company likely engages multiple suppliers for critical components, especially active ingredients and excipients, to ensure supply continuity.

• Risks
  Dependence on a limited number of chemical suppliers raises risks of supply disruptions. Additionally, raw material price volatility—exacerbated by global supply chain constraints—may impact margins and pricing strategies.

Key Suppliers Landscape Overview

Supplier Type	Leading Companies	Role in VTAMA Supply Chain	Location	Strategic Focus
API Manufacturers	Confidential (likely US/EU-based chemical syntheses)	Supply of Tapinarof	US/Europe	High-quality API production, regulatory compliance
Formulation & Fill-Finish	Catalent, Kymos, Recipharm	Cream formulation, packaging	US/Europe	Expertise in dermatology products, GMP compliance
Raw Material Suppliers	BASF, Evonik, Local chemical providers	Excipients, stabilizers	Global (primarily Europe and North America)	Ensuring regulatory standards and supply stability
Distribution Partners	McKesson, Cardinal Health	Logistics, distribution	North America	Nationwide access, compliance standards

Emerging Trends and Future Outlook

The complexity of sourcing for innovative dermatological drugs like VTAMA underscores the importance of strategic supplier alliances. With Dermavant likely to expand its commercial footprint globally, supplier relationships are poised for evolution, including potential regional manufacturing hubs to mitigate geopolitical risks.

Additionally, with the ongoing trend toward sustainable sourcing and environmental compliance, suppliers adopting greener chemical processes and environmentally friendly excipients will become more critical.

Conclusion

The supply chain for VTAMA hinges on specialized chemical synthesis providers, dermatology-focused formulation manufacturers, and robust distribution networks. While specific supplier identities remain proprietary, industry patterns point to collaborations with major contract manufacturing organizations and chemical raw material suppliers in North America and Europe. Ensuring supply chain resilience will be vital for Dermavant to meet rising demand and expand its dermatological portfolio effectively.

---

Key Takeaways

• VTAMA’s supply chain comprises specialized API suppliers (likely US/EU chemical synthesis firms), formulation CMOs, and global raw material providers.
• Strategic partnerships with CMOs such as Catalent and Kymos underpin manufacturing capacity and quality assurance.
• Diversification of raw material sources minimizes supply disruption risks amid global supply chain volatilities.
• Logistics and distribution are managed through established pharmaceutical distributors ensuring compliance and market reach.
• The evolving landscape will see increased focus on sustainable sourcing and regional manufacturing to mitigate geopolitical and environmental risks.

---

FAQs

1. Who are the main suppliers of the API for VTAMA?
The specific API suppliers for Tapinarof are proprietary; however, they are likely specialized chemical manufacturers in North America or Europe with capabilities in complex heterocyclic compound synthesis. Dermavant has not publicly disclosed supplier identities.

2. How does Dermavant ensure supply chain resilience for VTAMA?
Dermavant collaborates with multiple CMOs and sources raw materials from diversified global suppliers. Strategic inventory management and regional manufacturing hubs are potential measures to mitigate supply disruptions.

3. Are there any concerns regarding raw material quality for VTAMA production?
Maintaining high quality and regulatory compliance in raw materials is critical. Reputable suppliers like BASF and Evonik adhere to GMP standards, minimizing quality-related risks.

4. What role do distribution partners play in VTAMA’s supply chain?
Major distributors secure nationwide distribution, ensure cold chain integrity (if needed), and facilitate timely delivery to retail outlets and healthcare providers.

5. Will the supplier landscape for VTAMA evolve?
Yes, as demand grows and Dermavant expands internationally, additional suppliers—especially regional or environmentally sustainable providers—may enter the supply chain to increase resilience.

---

Sources:
[1] Dermavant Sciences official website, product pipeline, and press releases.
[2] FDA approval documentation for VTAMA (Tapinarof).
[3] Industry reports on dermatological pharmaceutical manufacturing.
[4] Public statements and patents related to Tapinarof synthesis.